To ask the Secretary of State for Health, pursuant to the Answer of 14 October 2015 to Question 10868, on blood diseases: drugs, when NHS England plans to take a decision on the development of a clinical commissioning policy for extended half-life products; what discussions NHS England has had to date on such a clinical commissioning policy; and if he will make a statement.
30 October 2015
The timing of the tender is effectively predicated on the availability of licensed products. The Department is in dialogue with those suppliers understood to be concerned in this market to understand their potential capabilities.
NHS England has made no decision to develop a clinical commissioning policy for 'extended half-life products'. The potential need for policy will remain under review by the Clinical Reference Group with input from the Department’s Commercial Medicines Unit, as manufacturer’s products achieve licence and procurements are completed.